Detrusor overactivity--an update.
Toozs-Hobson
P
P
Birmingham Women's Hospital, UK.
Elnaqa
A
A
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004599:Electric Stimulation Therapy / Q000295:instrumentation; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D019736:Prostheses and Implants; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000209:etiology / Q000534:rehabilitation; D016055:Urinary Retention / Q000188:drug therapy* / Q000534:rehabilitation
D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A